| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3864127 | The Journal of Urology | 2013 | 5 Pages |
Abstract
Intravesical gemcitabine has activity in high risk nonmuscle invasive bladder cancer and offers an option for patients with recurrence after bacillus Calmette-Guérin who are not suitable for cystectomy. However, less than 30% of patients had a durable response at 12 months even with maintenance therapy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Eila C. Skinner, Bryan Goldman, Wael A. Sakr, Daniel P. Petrylak, Heinz-Josef Lenz, Cheryl T. Lee, Shandra S. Wilson, Mitchell Benson, Seth P. Lerner, Cathy M. Tangen, Ian M. Thompson,